Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06119217 | Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients | PHASE2 | ACTIVE NOT_RECRUITING | 194 | — | — | Mar 25, 2024 | Jun 1, 2027 | Dec 4, 2024 | 64 | United States, Australia +5 |
PFS is defined as the time from randomization until first documentation of progression or death from any cause, whichever occurs first
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | TTX-030 plus nab-paclitaxel and gemcitabine |
| Arm 2 | EXPERIMENTAL | TTX-030 plus budigalimab plus nab-paclitaxel and gemcitabine |
| Arm 3 | ACTIVE_COMPARATOR | Nab-Paclitaxel and gemcitabine |
| Name | Type | Description |
|---|---|---|
| TTX-030, nab-paclitaxel and gemcitabine | COMBINATION_PRODUCT | Dose and schedule per protocol |
| TTX-030, budigalimab, nab-paclitaxel and gemcitabine | COMBINATION_PRODUCT | Dose and schedule per protocol |
| Nab-Paclitaxel and gemcitabine | COMBINATION_PRODUCT | Dose and schedule per protocol |
Abbreviated Inclusion Criteria: 1. Age 18 years or older, is willing and able to provide informed consent 2. Histologically or cytologically confirmed diagnosis of metastatic PDAC. 3. No prior systemic treatment for metastatic disease. 4. Evidence of measurable disease per RECIST 1.1. 5. Appropriat...